tbuckley/cabot-search huggingface dataset:
Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferon therapy.
Authors: M. Krogh, I. J. Christensen, M. Bouwhuis, J. S. Johansen, H. Schmidt, J. Hansson, S. Aamdal, A. Testori, A. M. Eggermont, L. Bastholt
Journal: Journal of Clinical Oncology (2010)

8587 Background: YKL-40 is a growth factor secreted by cancer cells and macrophages. High serum YKL-40 is related to poor prognosis in stage I-II and IV melanoma. Methods: YKL-40 was determined by ELISA (Quidel) in serum samples from 1041 patients (pts) (400 F/641 M, median age 50, range 18-77) included in clinical trials of adjuvant interferon (IFN) treatment of stage IIB-III melanoma pts (the Nordic Study [n = 602], EORTC 18952 [n = 246], and EORTC 18991, untreated pts only [n = 193]). Patients were randomized to observation, or one or two years of adjuvant IFN alfa-2b. Overall, 457 (44%) pts died during follow-up. Serum samples were collected at baseline (i.e. at inclusion after surgery), during treatment and at follow-up every three to six months up to 10 years. Results: Pretreatment YKL-40 levels were not associated with disease stage, ulceration, Breslow thickness, or Clark's level. Univariate analysis of baseline YKL-40 (log2 transformed) in the 299 untreated patients demonstrated an association of higher levels with short overall survival (OS) (HR = 1.28; 95% CI: 1.05-1.57, p = 0.015). This association could not be shown for the IFN treated patients from the Nordic Study and EORTC 18952 in a pooled analysis (1 year treatment with interferon: HR = 1.12, 0.88-1.42, p = 0.35; 2 years: HR = 1.08, 0.86-1.35, p = 0.54). Analysis of updated YKL-40 levels sampled longitudinally and stratified by treatment showed that an increase in the YKL-40 level compared to the previous measurements was significantly associated to shorter OS in all treatment arms with HR for a two-fold difference ranging from 1.40 to 1.68. Conclusions: High serum YKL-40 in patients after surgery for stage IIB-III melanoma is associated with poor survival in untreated patients, but not in IFN treated patients from the Nordic Study and EORTC 18952. Increasesin serum YKL-40 during adjuvant IFN treatment or follow-up is associated with poor survival. When more effective treatments for melanoma are developed, it may be important to identify patients with recurrence early, and serial analysis of YKL-40 may be a useful tool for this purpose. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Schering-Plough Schering-Plough Schering-Plough
DNA Adducfs, Protein Adducts, and Sister Chromatid Exchange in Cigarette Smokers and Nonsmokers&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: F P Perera, R M Santella, D Brenner, M C Poirier, A A Munshi, H K Fischman, J Van Ryzin
Journal: JNCI Journal of the National Cancer Institute (1987)

In order to validate markers of internal dose and biologically effective dose of carcinogens, a battery of measurements was made on blood samples from 22 smokers and 24 nonsmokers. The markers included immunoreactivity in an enzyme-linked immunosorbent assay (ELISA) quantified in white blood cells with the use of a polyclonal anti-benzo[a]pyrene diol epoxide-I-DNA antibody, 4-aminobiphenyl hemoglobin (4-ABP-Hb) adducts measured by negative chemical ionization mass spectrometry, sister chromatid exchange (SCE) in cultured lymphocytes, and cotinine in plasma measured by radioimmunoassay. Several blood samples were drawn from each subject. In blood samples 1 and 3 having detectable levels of DNA adducts, mean femtomole-per-microgram levels were consistently higher among smokers compared to nonsmokers. The borderline significance of this difference may be attributable to the small numbers of subjects. Consistently higher adduct levels were seen in females compared to males. In sample 3, adduct levels were significantly correlated with measurements of active smoking in smokers and with passive smoking in nonsmokers. By contrast to the ELISA data, which may reflect cumulative exposure from multiple background sources, the 4-ABP-Hb assay was able to distinguish clearly between smokers and nonsmokers. SCEs were significantly elevated in the smokers compared to nonsmokers. Also observed were significant correlations between 4-ABP-Hb and both cotinine and SCEs, as well as a positive correlation between the 4-ABP-Hb and DNA adduct levels (sample 3) that was highly significant. The correlation between DNA and 4-ABP-Hb adducts was significant in smokers but not nonsmokers (sample 3). These results support the need for batteries of markers to detect and to quantify the carcinogenic dose to humans resulting from both specific and "background" environmental exposures.
Need for a forum where young doctors can express feelings about patients
Authors: Jacq L Hawkins
Journal: BMJ (2016)

Although I agree with Cocksedge that labelling patients with the word “heartsink” probably isn’t helpful,1 I think there’s an element of denial or possibly political correctness in not recognising that it can describe just how you feel. If my heart sinks, it is because a patient keeps returning even though I have …
Phase I study of ixabepilone given every other week in combination with irinotecan in patients with advanced malignancies
Authors: S. J. Faivre, C. Delbaldo, P. Pautier, V. Boige, S. Henriet, J. P. Armand, B. Grau, F. Namouni, R. Peck, E. Raymond
Journal: Journal of Clinical Oncology (2004)

2051 Background: Ixabepilone, a semisynthetic novel derivative of Epothilone B, is active against paclitaxel resistant and sensitive tumors. In phase I monotherapy studies, myelosuppression and neuropathy were dose limiting. This combination phase I study aims to establish the Maximal Tolerated Dose (MTD) of Ixabepilone with Irinotecan, characterize dose limiting toxicities (DLTs) and the safety profile of the combination as well as describe antitumor activity. Methods: Ixabepilone and Irinotecan were given intravenously, on days 1 and 14 of a 28-day cycle, to patients (pts) with advanced solid tumors previously treated with up to 3 prior chemotherapy regimens. Plasma levels of both drugs were measured on the first course. Results: Thirty pts have received 5 dose levels. Data are available for 26 pts (15 males/ 11 females). Median age was 52 yrs [25–71]. A total of 116 ixabepilone/irinotecan courses have been administered. Tumor types consisted of lung cancer (8 pts), gynecological cancer (4 pts), GI cancer (6 pts), breast cancer (2 pts), others (6 pts). So far MTD has not been reached. Summary of dose escalation and DLTs at cycle 1 is provided in the following table: The combination has antitumour activity with 4 partial responses in pts with non-small cell lung cancer (2), small-cell lung cancer (1), and carcinoma of unknown primary (1). Conclusion: Full doses of irinotecan (180 mg/m2) can be combined every 2 weeks with up to 25 mg/m2 of ixabepilone (30 mg/m2 is ongoing) with evidence of antitumor activity. Final assessment of the recommended dose as well as pharmacokinetic data will be presented at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb
Effectiveness of chemotherapy administration and time to cystectomy following neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in the academic and community settings.
Authors: Tracy Lynn Rose, Allison Mary Deal, Ethan M. Basch, Paul Alphonso Godley, Kimryn Rathmell, William Y. Kim, Young E. Whang, Mary Dunn, Matthew Edward Nielsen, Raj Pruthi, Eric Wallen, Michael Woods, Angela Smith, Matthew I. Milowsky
Journal: Journal of Clinical Oncology (2015)

359 Background: Neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy is the standard of care for MIBC. Many patients are referred to an academic medical center (AMC) for cystectomy but receive NAC in the community setting. It is unknown if administration of NAC in the community is associated with differences in type of NAC received, pathologic response rate (pT0), and time to cystectomy as compared to NAC administered at an AMC. Methods: This is a retrospective study of 135 patients referred to a single AMC with MIBC (cT2a-T4-Nx-M0) between 1/2012 and 1/2014. We analyzed patient demographics, clinical stage, treatment, pT0 and time to cystectomy in patients who received NAC at our AMC compared to those referred to the community setting. Comparisons were made using Wilcoxon rank-sum, Fisher’s exact test, and multivariable linear regression. Results: Median age was 70, 73% were male, and 83% Caucasian. Most patients (73.3%) had clinical stage II disease. 94 (69.6%) underwent cystectomy and of those, 47 (50%) received NAC. 34% received NAC at our AMC and 66% in the community. Age, sex, clinical stage, and renal function did not differ significantly between those who received NAC in the community and those at our AMC. Those who received NAC in the community had a similar total dose of cisplatin (median 280 mg/m 2 for both groups, p=0.89) and pT0 rate (25% vs. 30%, p=0.72) compared to those who received NAC at our AMC. However, community administration of NAC was associated with a significantly prolonged time from initial visit to cystectomy (median number of days 128 vs. 162, p&lt;0.01). This remained significant after adjusting for age and renal function (p=0.04). Conclusions: Patients with MIBC treated with NAC in the community as compared to an AMC received similar chemotherapy and achieved comparable pT0 rates suggesting the effective implementation of NAC in the community setting. However, those who received NAC in the community had a significantly longer time from initial visit to cystectomy, suggesting a delay in the transfer of care between settings and an area for improvement.
Abstract 11460: Chronic Intermittent Low Level Transcutaneous Electrical Stimulation of the Auricular Branch of the Vagus Nerve Improves Left Ventricular Remodeling in Conscious Dogs With Healed Myocardial Infarction
Authors: Zhuo Wang, Lilei Yu, Songyun Wang, Bing Huang, Kai Liao, Gaowa Saren, Hong Jiang
Journal: Circulation (2014)

Introduction: Vagus nerve stimulation (VNS) attenuates left ventricular remodeling after myocardial infarction (MI) by improving the imbalance of autonomic nervous system. Our previous study found Low-level tragus stimulation (LL-TS) had the same antiarrhythmic effects as VNS by regulation of the autonomic nervous system. Hypothesis: Chronic intermittent LL-TS could attenuate left ventricular remodeling in conscious dogs with healed myocardial infarction. Methods: Thirty beagle dogs were randomly divided into three groups. LL-TS group (n=10) and MI group (n=10) underwent left anterior descending coronary artery and all major diagonal branches ligation to introduce MI under general anesthesia. Control group (n=10) underwent sham surgery. Auricular vagus nerve stimulation (frequency 20Hz, pulse width 1ms) with duty cycle of 5s on and 5s off was delivered to the bilateral tragus in external auditory canal with ear-clips connected to a custom-made stimulator. The voltage slowing sinus rate was used as the threshold for setting LL-TS at 80% below that. The actual voltage of stimulation was in the range of 16 to 24V that did not cause any heart rate changes. LL-TS group was given four hours of LL-TS at 7-9AM and 4-6PM on conscious dogs from the day of MI introduction to the end of 90-day follow-up, MI group and control group were given no stimulations. Results: At the end of 90-days follow-up LL-TS group significantly reduced left ventricular dilatation, improve left ventricular contractile and diastolic function, reduced mean infarct size by about 50% compared with MI group. Also LL-TS treatment alleviated cardiac fibrosis around infarction border and significantly decreased protein level of collagen I, collagen III, TGF-β1, MMP-9 in noninfarcted left ventricular free wall tissue after MI. Moreover, the plasma level of hs-CRP, NE and NT-proBNP in LL-TS group was significantly lower than MI group from the 7th day to the end of follow-up. Conclusions: Chronic intermittent low-level transcutaneous electrical stimulation of the auricular branch of the vagus nerve can attenuate left ventricular remodeling and improve cardiac function in conscious dogs with healed myocardial infarction.
Heterotransplantation of Human Malignant Tumors in “Nude” Thymusless Mice. II. Malignant Tumors Induced by Injection of Cell Cultures Derived From Human Solid Tumors 2
Authors: B. C. Giovanella, J. S. Stehlin, L. J. Williams
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Heterotransplantation of Human Malignant Tumors in "Nude" Thymusless Mice. II. Malignant Tumors Induced by Injection of Cell Cultures Derived From Human Solid Tumors Get access B. C. Giovanella, B. C. Giovanella Search for other works by this author on: Oxford Academic PubMed Google Scholar J. S. Stehlin, J. S. Stehlin Search for other works by this author on: Oxford Academic PubMed Google Scholar L. J. Williams, Jr. L. J. Williams, Jr. 3Cancer Research Laboratory and Department of Pathology , St. Joseph Hospital, Houston, Tex. 77002. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 3, March 1974, Pages 921–930, https://doi.org/10.1093/jnci/52.3.921 Published: 01 March 1974 Article history Received: 20 September 1973 Accepted: 21 November 1973 Published: 01 March 1974
Erythroid Hypoplasia in Cats Inoculated With Feline Leukemia Virus 2
Authors: Edward A. Hoover, Gary J. KocIba, William D. Hardy, David S. Yohn
Journal: JNCI Journal of the National Cancer Institute (1974)

Severe anemia was induced in 13 of 15 cats inoculated at birth with preparations of the KT feline leukemia virus (FeLV). The disease was transmitted through 3 serial passages. The survival period for the affected cats was 49–179 days. Serial examination of blood and bone marrow revealed progressive, nonregenerative anemia associated with profound erythroid hypoplasia in the marrow. In the first FeLV passage, 2 of 7 anemic cats had concurrent focal lymphosarcoma confined to the marrow. No neoplasia was evident in the cats that developed anemia in the second and third serial passages. Serial blood smears of 3 inoculated cats were examined for FeLV group-specific antigens. FeLV antigens were detected in leukocytes of cats 5 weeks post inoculation, which was 4 weeks before the onset of anemia. The cats remained FeLV positive throughout the anemic period.
Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC)
Authors: M. G. Kris, A. Sandler, V. Miller, M. Cespon, M. Zakowski, B. Pizzo, E. Venkatraman, J. Gomez, D. Johnson, D. Carbone
Journal: Journal of Clinical Oncology (2004)

7062
Retroviral Marking of Canine Bone Marrow: Long-Term, High-Level Expression of Human Interleukin-2 Receptor Common Gamma Chain in Canine Lymphocytes
Authors: Todd Whitwam, Mark E. Haskins, Paula S. Henthorn, Jennifer N. Kraszewski, Sandra E. Kleiman, Nancy E. Seidel, David M. Bodine, Jennifer M. Puck
Journal: Blood (1998)
Histone Deacetylase 11 (HDAC11) Is a Novel Regulator In The Expansion Of MDSCs Via The Transcription Factor C/EBP-β
Authors: Jie Chen, John Powers, Jennifer Rock-Klotz, Susan Deng, Allison Distler, Fengdong Cheng, Alejandro Villagra, Eduardo M. Sotomayor, Eva Sahakian, Javier Pinilla-Ibarz
Journal: Blood (2013)
Hepatic intra-arterial chemotherapy in anthracyclin-taxane- and vinorelbine-pretreated breast cancer patients
Authors: C. Zanon, M. Airoldi, F. Pedani, M. Bortolini, P. Simone, F. Bruno, P. Gaglia, L. Maganuco, M. Grosso
Journal: Journal of Clinical Oncology (2005)

841 Background: Metastatic breast cancer is a challenge for medical oncologists and the mean survival after the neoplasm systemic diffusion is around 2 years. After the bone, the liver is the second metastatic site, and the hepatic relapse after 1–2 lines of chemotherapy is generally an incurable disease. Hepatic intra-arterial chemotherapy is a historical assessed procedure in colon-rectal liver mts, and recently Japanese experiences enlarged the regional application to mammary hepatic metastases with an interesting overall responses and a possible survival improvement. In the last 9 years, in our center we are applying a percutaneous implantation of hepatic arterial Port-a-Cath for secondary and primitive liver cancers, and recently we have extended these procedure to the non colon-rectal liver mts. Methods: From 2000 to 2002 we implanted our percutaneous arterial Port-a-Cath in 20 patients affected by more than 5 breast hepatic mts as the only site of disease diffusion. All the patients were pretreated with 2–3 lines of Anthraciclynes, Taxanes and Vinorelbine schedules. Median age 58 y., median ECOG PS 1, previous chemotherapic lines: 2 lines 55%- 3 lines 45%. Intra-arterial schedula infused: Cisplatin 8–10 mg/m2 x 2 /d d 1–> 3, Mitomycin-C 2 mg/m2 x 2/d d 1–> 3, 5-FU 1 gr/m2/c.i. x 72 hours, every 4–6 weeks for 6–8 courses (median interval = 5 weeks; median given courses = 6). Number of mts > 5 25%, 6 to 10 55%, > 10 20%. Results: We observed: CR 15% (12 +, 18+, 24 months), PR 40% (median 6 months), SD 20%, median progression free survival 8.5 months, median survival 13 months. Catheter related side effects: gastric-duodenal ulcer 15%, catheter displacement 10% (repositioned). Main systemic side effects (WHO score): PTL G3 10%, WBC G4 10%. Conclusions: Regional intra-arterial hepatic chemotherapy seems to be a possible option for heavily pretreated breast liver mts for the number of objective responses, for the interesting survival and for the local and systemic safety of the intra-arterial schedula proposed. The percutanous mini-invasive approach allows a safe application of the regional treatment. No significant financial relationships to disclose.
Standardize plasma sample collection method for biomarker searching study in oncology
Authors: F. Kong, L. Wang, L. Zhao, Y. Chen, M. Anscher, X. Fu, C. Bai, L. Wang, T. S. Lawrence, P. Okunieff, A. P. Dicker
Journal: Journal of Clinical Oncology (2008)

22163 Background: Sample quality is critical for biomarker searching in oncology. Platelet degradation and contamination in plasma has a remarkable impact on many blood markers. Platelet factor 4 (PF4) can be used as a surrogate of this condition and a monitor for the sample quality. This multicenter study aimed to validate the impact of blood sample handling process on platelet degradation/contamination and to establish an optimal method for platelet poor plasma. Methods: Six centers participated. Blood were drawn from 12–13 healthy volunteers from each center. Blood samples were prepared to serum or plasma by 9 methods (table). These samples were sent to the University of Michigan (American samples) or Peking Union Medical College Cancer Hospital (Chinese samples) for measurement of PF4 with ELISA. Paired-T test was used for statistic analysis. Results: A total of 74 subjects enrolled. The methods generated the lowest level of PF4 was the ones prepared by 3000×g for 30 min, and with blood samples set on ice <30 min. Comparing to results of this, PF4 was significantly higher in serum samples (P5 min (P<0.001), inadequate spinning gravity (P<0.001), and 3–4 hours blood setting on ice. There was no significant difference among PF levels of each method between centers. The mean PF4 levels of all centers of each method are shown in table. There was no significant difference in PF4 levels between Chinese and American subjects. Conclusion: This multicenter study demonstrates 7 conditions to cause platelet degradation and optimal methods of plasma preparation. Future blood maker study should take this into consideration. Platelet factor 4 (PF4) levels in different handling methods Sample Setting Temperature Setting Time (Min) RCF and Duration PF4 (ng/ml) Plasma 1 On ice 5 3,000×g 30 min 27.9 ± 29.6 Plasma 2 On ice 30 3,000×g 30 min 23.0 ± 23.2 Plasma 3 On ice 240 1,200×g 10 min 50.1 ± 36.3 Plasma 4 On ice 240 3,000×g 30 min 26.8 ± 26.4 Plasma 5 RT 5 3,000×g 30 min 55.9 ± 45.1 Plasma 6 RT 30 3,000×g 30 min 83.2 ± 59.1 Plasma 7 RT 60 3,000×g 30 min 82.6 ± 38.5 Serum 1 On ice 240 3,000×g 30 min 67.3 ± 54.9 Serum 2 RT 60 3,000×g 30 min 124.7 ± 79.2 RT: Room temperature; RCF: relative centrifugation force No significant financial relationships to disclose.
Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform exanthema caused by the EGFR-inhibitor cetuximab
Authors: A. Wollenberg, K. Katzer, J. Tietze, N. Moosmann, J. Kroth, T. Ruzicka, V. Heinemann
Journal: Journal of Clinical Oncology (2008)

20652 Background: Acneiform exanthema are the most common side effects during treatment with cetuximab, an epidermal growth factor receptor antibody for treatment of solid tumors, and can cause dose reductions, delays or discontinuation of cetuximab therapy. Since tumour response to cetuximab appears to be correlated with the severity of acneiform eruptions, successful treatment of the skin lesions is needed. Methods: An uncontrolled case series study evaluated the effects of topically applied nadifloxacin cream combined with prednicarbate cream to treat acneiform eruptions caused by cetuximab based chemotherapy. Twenty-nine patients received standard dose cetuximab (400mg/m2 starting dose followed by 250mg/m2 maintenance dose once weekly) predominantly for treatment of colorectal cancer. Nadifloxacin cream and prednicarbate cream were each applied once daily in 8 patients with mild, 13 patients with moderate, and 8 patients with severe acneiform exanthema. Clinical assessment was performed before, as well as 1, 2 and 6 weeks after the initiation of treatment using a novel severity score for acneiform eruptions evaluating the intensity of erythema, distribution density of lesions, population, pustulation and crust formation (WoMo-Score). Results: The patients showed a significant (p≤0.05) improvement of skin lesions, i.e. a reduction of papules, pustules and erythema, between all 4 time points analyzed. In addition, subjective symptoms such as pruritus, tenderness of the involved skin and pain were reduced. An initial burning sensation and erythema following nadifloxacin cream was an infrequently reported side effect. Conclusions: Once daily topical treatment with nadifloxacin cream and prednicarbate cream is a clinically useful, efficient and well tolerated regimen for cetuximab-induced acneiform exanthema, which facilitates the use of cetuximab and merits further investigation. No significant financial relationships to disclose.
Abstract 16: Intraaortic Aqueous Oxygen Infusion in a Swine Model of Acute Isovolemic Anemia
Authors: Yazan Khouri, Lakshmi Muthukumar, Neelima Katukuri, Ibrahim Shaik, Subhashish Agarwal, Kiran kumar R Mangalpally, Salik Jahania, Robert Hammond, Saptarshi Bandyopadhyay, Petar Prcevski, Janine Mattei, James Spears
Journal: Circulation (2013)

Background: Intracoronary perfusion with hyperbaric aqueous oxygen (AO) during reperfusion in anterior STEMI patients has been shown to reduce infarct size. Technical limitations of the method prec...